Literature DB >> 34563709

Lack of latent tuberculosis (TB) screening and delay in anti-retroviral therapy initiation in HIV-TB co-infection: an 11-year study in an intermediate TB-burden country.

Vannesa Yue May Teng1, Yan Ting Chua2, Eunice En Ni Lai2, Shilpa Mukherjee2, Jessica Michaels2, Chen Seong Wong3, Liang Shen4, Yee Sin Leo5, Barnaby Young5, Sophia Archuleta6, Catherine W M Ong7.   

Abstract

OBJECTIVES: To examine the prevalence and characteristics of HIV-tuberculosis (TB) co-infected patients in Singapore, an intermediate TB-burden country.
METHODS: Retrospective data across 11 years was obtained from the National University Hospital (NUH), a quaternary hospital and the National Centre for Infectious Diseases (NCID), the national HIV center.
RESULTS: From December 2005 to December 2016, 4015 HIV-infected patients were managed at NUH and NCID, of whom, respectively, 48 and 272 were diagnosed with active TB disease. Only 2 patients (0.6%) were screened for latent TB infection on HIV diagnosis. Mean CD4 count at TB diagnosis was 125.0 ± 153.9 cells/mm3. More patients with HIV diagnosed ≥6 weeks before TB (41%) were associated with CD4 counts >200 cells/mm3 than patients with TB diagnosed ≥6 weeks before HIV (2%). Of 124 (38.6%) HIV-TB patients with CD4 count ≤50 cells/mm3, only 18 (14.2%) started anti-retroviral therapy (ART) in <2 weeks. Of patients with pulmonary TB, 33.5% had normal chest x-ray.
CONCLUSIONS: Latent TB infection screening in HIV-infected patients is low, and ART initiation is delayed in HIV-TB patients with CD4 ≤50 cells/mm3. Pulmonary TB patients with HIV can be infectious despite normal chest x-ray. Clinical practices can be further improved to benefit HIV-TB patients.
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  HIV; Tuberculosis; latent tuberculosis infection

Mesh:

Year:  2021        PMID: 34563709     DOI: 10.1016/j.ijid.2021.09.048

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  2 in total

1.  Clinical standards for the diagnosis, treatment and prevention of TB infection.

Authors:  G B Migliori; S J Wu; A Matteelli; D Zenner; D Goletti; S Ahmedov; S Al-Abri; D M Allen; M E Balcells; A L Garcia-Basteiro; E Cambau; R E Chaisson; C B E Chee; M P Dalcolmo; J T Denholm; C Erkens; S Esposito; P Farnia; J S Friedland; S Graham; Y Hamada; A D Harries; A W Kay; A Kritski; S Manga; B J Marais; D Menzies; D Ng; L Petrone; A Rendon; D R Silva; H S Schaaf; A Skrahina; G Sotgiu; G Thwaites; S Tiberi; N Tukvadze; J-P Zellweger; L D Ambrosio; R Centis; C W M Ong
Journal:  Int J Tuberc Lung Dis       Date:  2022-03-01       Impact factor: 3.427

2.  The crucial need for tuberculosis translational research in the time of COVID-19.

Authors:  Fei Kean Loh; Pei Min Thong; Catherine W M Ong
Journal:  Lancet Respir Med       Date:  2022-03-23       Impact factor: 102.642

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.